The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo nodularis in adults, according to the manufacturer Galderma. Those eligible must be candidates for systemic therapy. The announcement on February 14 marks the first approval for …
Leave a Comment Leave a Comment
